MDS Patient Panel
Topic(s)
Myelodysplastic Syndromes (MDS)
In this webinar, patients diagnosed with MDS discuss their patient journey and share their personal experiences.
Myelodysplastic Syndromes (MDS)
CCUS and MDS - Webinar for Patients
Topic(s)
Myelodysplastic Syndromes (MDS)
Presenter(s)
Kelly Bolton, MD, PhD
Eytan Stein, MD
In this webinar, Drs. Kelly Bolton and Eytan Stein discuss CCUS (clonal cytopenia of undetermined significance) and the connection to MDS.
Integrative Medicine
Topic(s)
Living Well with Bone Marrow Failure
Presenter(s)
Nathan R. Handley, MD
In this webinar, Dr. Nathan Handley discusses what is integrative medicine and how it can be part of your treatment plan. He answers audience questions in the recording.
Caregivers - Take Care but HOW????
Topic(s)
Pediatric Bone Marrow Failure Diseases
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Acute Myeloid Leukemia (AML)
Presenter(s)
Jane Meier Hamilton, RN, MSN
In this webinar, Jane Hamilton discusses how and why it is important for caregivers to practice self care. The entire interactive session was recorded.
Haploidentical Transplant with Post-Transplant Cyclophosphamide for Acute Myeloid Leukaemia and Myelodysplastic Syndromes Patients: The Role of Previous Lines of Therapy
Background: Allogeneic haematopoietic stem-cell transplant is an option, potentially curative, for high-risk acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) patients.
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial
Background: Sabatolimab Sabatolimab: Sabatolimab (MBG453) is a novel immuno-myeloid therapy that binds to TIM-3 on immune cells, facilitating antileukemic immune activation and phagocytic
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study
Background: The DNA methyltransferase inhibitors azacitidine azacitidine: It works by reducing the amount of methylation in the body.
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial
Background: Unmet medical needs remain in patients with red blood cell transfusion red blood cell transfusion: A pro
T cell dysfunctions in myelodysplastic syndromes
Escape from immune surveillance is a hallmark of cancer.